Neil Chanchlani

Oct 28, 2024 | bmjmedicine.bmj.com | Neil Chanchlani |Lisa K Stamp |Andrew Day |Vivien Lou Chen

Low certainty evidence suggests a proactive approach during maintenance therapy for patients treated with infliximabAbout 1% of adults and children globally,1 and between 5% and 7% of those living in western societies,2 have a chronic immune mediated inflammatory condition. Infliximab and adalimumab, which are anti-tumour necrosis factor (TNF) treatments, are the most widely used biologics for treating immune mediated inflammatory disorders.

Nov 13, 2023 | bmj.com | David Phizackerley |Neil Chanchlani |Fraz A Mir |BMA House

David Phizackerley, deputy editor1, Neil Chanchlani, clinical editor2, Fraz Mir, consultant physician3 1Drugs and Therapeutics Bulletin, BMA House, London WC1H 9JR, UK 2The BMJ, BMA House, London, UK 3Addenbrooke's Hospital, Cambridge, UK Correspondence to: N Chanchlani nchanchlani{at}bmj.com The BMJ’s new “practical prescribing” series aims to improve decision making Written prescriptions for medicinal products can be traced back over 4000 years.1 Little is known about the clinical efficacy...